Navigation Links
Pharmos Corporation Reports 2007 Third Quarter Results
Date:10/30/2007

ISELIN, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the third quarter ended September 30, 2007. Net loss decreased 17% to $3.5 million, or $0.14 per share, for the third quarter 2007, from a net loss of $4.2 million, or $0.22 per share, in the third quarter 2006. Cash and short-term investments totaled $13.9 million at September 30, 2007.

The decrease in net loss for the third quarter 2007 is due to a 21% decrease in operating expenses to $3.7 million from $4.7 million in the third quarter 2006. Gross research and development expenses increased 16% to $2.7 million compared to $2.3 million in the third quarter 2006. A decrease in research and development grant receivables to $0.2 million in the third quarter 2007 from $0.4 million in the third quarter 2006 impacted net research and development expenses, which totaled $2.5 million compared to $1.9 million in the third quarter 2007 and 2006, respectively. The increase in net research and development expenses was more than offset by lower general and administrative expenses, which decreased 56% to $1.2 million from $2.7 million in the third quarter 2006. The decrease in operating expenses was partially offset by a decrease in net other income to $0.2 million in the third quarter 2007 from $0.5 million in the third quarter 2006, due primarily to a decrease in interest income.

Gross research and development expenses in connection with Pharmos' leading clinical program, dextofisopam for irritable bowel syndrome (IBS), were $1.1 million for the quarter, during which the Company advanced its ongoing Phase 2b study of dextofisopam. The Phase 2b study, which commenced in June 2007, is expected to enroll approx
'/>"/>

SOURCE Pharmos Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. Sonic Foundry reports GAAP loss as Q2 revenues rise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- The 12th Cold Chain GDP & Temperature Management ... at the John B. Hynes Convention Center. The remarkable ... for a weeklong conference attracting industry executives from around ... to cover the industry,s most pressing topics, with an ... range products, GDP compliance requirements and supply chain integrity. ...
(Date:9/29/2014)...  Perrigo Company plc (NYSE: PRGO ... a portfolio of preclinical research assets, which it ... Corporation plc, to drug discovery and development company, ... will receive an upfront payment in addition to ... future sales derived from the portfolio. ...
(Date:9/29/2014)... Sept. 29, 2014  Xcenda, the strategic consulting ... pharmaceutical sourcing and distribution service companies, recently conducted ... This research was analyzed in an economic model ... with an increase in life years and a ... population-level coffee consumption across the United ...
(Date:9/29/2014)... Westbridge Agricultural Products announced today ... highly effective new tool for organic growers. SUPPRESS™ ... contact herbicide for post-emergent, non-selective weed control for ... The formulation is an emulsifiable concentrate that has ... (OMRI) for use in organic food production. , ...
Breaking Biology Technology:12th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... CHARENTON-LE-PONT, France, January 10 Essilor,of America, Essilor ... in the United States with the acquisition,of Interstate ... independent,laboratories. Interstate,s two laboratories in Mansfield, Ohio and,Indianapolis, ... The,company has full-year sales of US$26 million and ...
... of,Maryland, Baltimore (UMB) BioPark today announced that Gliknik ... in the BioInnovation,Center, located in UMB BioPark,s Building ... for autoimmune diseases,and cancer, the foundation of which ... Professor and Chairman of the Department of,Otorhinolarynogology, University ...
... 9 Burrill Merchant Banking acted as,exclusive financial ... partnering of bilastine with the Menarini Group (Italy). ... bilastine rights in Europe,and other regions to Menarini ... is a new highly selective H1 antihistamine for ...
Cached Biology Technology:University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two 2Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement 2
(Date:9/29/2014)... PULLMAN, Wash. Scientists at Washington State University ... specifically, Granny Smith apples may help prevent ... be the first to assess these compounds in ... in October,s print edition of the journal ... apples are a good source of these nondigestible ...
(Date:9/29/2014)... have found compounds that boost liver detoxification enzymes nearly ... placethe crushed seeds left after oil extraction from an ... compounds in Camelina sativa seed, also known ... phytochemicals that work together synergistically far better than they ... supplement because its bioactive ingredients increase the liver,s ability ...
(Date:9/29/2014)... is often deemed inaccessible or esoteric. Yet in the ... in our daily lives and a decisive role in ... behind the scenes. , UC Santa Barbara,s Paul Atzberger, ... assistant professor of mechanical engineering, often works in areas ... research published in the Proceedings of the National ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4
... institutions, led by Stanford University and Brown University, have ... federal funding to learn both how the brain and ... can be done to encourage recovery from injury. ... developing the neurotechnology to ultimately enable an entirely new ...
... find answers about ovarian cancer, researchers now have something to ... been using the chicken as a model to study this ... with flaxseed decreases severity of ovarian cancer and increases survival ... of alpha-linolenic acid, one type of omega-3 fatty acid. Several ...
... normally infect rodents, but they are also infectious for ... symptoms in humans. Most importantly, these viruses have an ... any damage to healthy tissue. Therefore, scientists in the ... German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been ...
Cached Biology News:New Stanford-led program aims to produce insights into brain injury, recovery 2New Stanford-led program aims to produce insights into brain injury, recovery 3Flaxseed-fed chickens shed light on ovarian cancer 2Flaxseed-fed chickens shed light on ovarian cancer 3Viruses against cancer 2Viruses against cancer 3
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Biology Products: